File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Role for aspirin after total hip replacement?

TitleRole for aspirin after total hip replacement?
Authors
Issue Date2006
Citation
Journal Of Pharmacy Practice And Research, 2006, v. 36 n. 3, p. 214-217 How to Cite?
AbstractBackground: Deep vein thrombosis can occur in up to 60% of patients following major orthopaedic surgery. Routine prophylaxis against thromobembolic complications is now the standard of care in this setting. Pharmacological agents used include unfractionated heparin, low molecular weight heparin, factor Xa inhibitors (fondaparinux), vitamin K antagonists and aspirin. Aim: To review the evidence and discuss the use of aspirin as thromboprophylaxis following elective total hip replacement, and consider its use in adult patients who refuse low molecular weight heparin. Method: A literature search was conducted to identify clinical studies, meta-analyses and clinical practice guidelines evaluating the use of aspirin as thromboprophylaxis following elective total hip replacement. Results: No large trials of acceptable quality which specifically compared aspirin with placebo following total hip replacement were identified. Clinical practice guidelines, meta-analyses and one clinical trial assessed aspirin against placebo or other agents used in thromboprophylaxis in major orthopaedic surgery, including elective total hip replacement. Conclusion: There is insufficient evidence to support the use of aspirin alone as thromboprophylaxis following elective total hip replacement.
Persistent Identifierhttp://hdl.handle.net/10722/145482
ISSN
2023 Impact Factor: 1.0
2023 SCImago Journal Rankings: 0.283
References

 

DC FieldValueLanguage
dc.contributor.authorChan, EWYen_HK
dc.date.accessioned2012-02-23T12:11:07Z-
dc.date.available2012-02-23T12:11:07Z-
dc.date.issued2006en_HK
dc.identifier.citationJournal Of Pharmacy Practice And Research, 2006, v. 36 n. 3, p. 214-217en_HK
dc.identifier.issn1445-937Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/145482-
dc.description.abstractBackground: Deep vein thrombosis can occur in up to 60% of patients following major orthopaedic surgery. Routine prophylaxis against thromobembolic complications is now the standard of care in this setting. Pharmacological agents used include unfractionated heparin, low molecular weight heparin, factor Xa inhibitors (fondaparinux), vitamin K antagonists and aspirin. Aim: To review the evidence and discuss the use of aspirin as thromboprophylaxis following elective total hip replacement, and consider its use in adult patients who refuse low molecular weight heparin. Method: A literature search was conducted to identify clinical studies, meta-analyses and clinical practice guidelines evaluating the use of aspirin as thromboprophylaxis following elective total hip replacement. Results: No large trials of acceptable quality which specifically compared aspirin with placebo following total hip replacement were identified. Clinical practice guidelines, meta-analyses and one clinical trial assessed aspirin against placebo or other agents used in thromboprophylaxis in major orthopaedic surgery, including elective total hip replacement. Conclusion: There is insufficient evidence to support the use of aspirin alone as thromboprophylaxis following elective total hip replacement.en_HK
dc.languageengen_US
dc.relation.ispartofJournal of Pharmacy Practice and Researchen_HK
dc.titleRole for aspirin after total hip replacement?en_HK
dc.typeArticleen_HK
dc.identifier.emailChan, EWY: ewchan@hku.hken_HK
dc.identifier.authorityChan, EWY=rp01587en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-33750022003en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33750022003&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue3en_HK
dc.identifier.spage214en_HK
dc.identifier.epage217en_HK
dc.identifier.scopusauthoridChan, EWY=14043219000en_HK
dc.identifier.issnl2055-2335-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats